Rokit Healthcare shares are showing strong performance. The news that the company is unveiling its artificial intelligence (AI)-based skin cancer (non-melanoma) regeneration platform at the Plastic Surgery The Meeting (PSTM), held in New Orleans, United States, until the 12th, and is pushing for entry into the North American market, appears to be influencing the stock price.
As of 9:26 a.m. on October 10, Rokit Healthcare was trading at 28,800 won, up 6.67% from the previous trading day.
The company described its regeneration platform as an innovative technology that aims for full regeneration of damaged skin, rather than simply providing a treatment method.
Clinical trials conducted on elderly patients with significantly reduced regenerative capacity due to skin cancer (non-melanoma) have attracted industry attention, as the results showed skin regeneration within an average of four weeks.
James J. Yoo, a professor at Wake Forest University School of Medicine, explained, "Rokit Healthcare's AI-based regeneration platform is a groundbreaking solution for addressing complex skin defects that have been difficult to treat with conventional methods." He added, "It can dramatically improve patients' quality of life by significantly accelerating recovery and delivering outstanding cosmetic results."
The Rokit Healthcare platform uses AI to perform a 3D precision analysis of the skin defect after lesion excision, and based on this, creates, implants, and regenerates a personalized skin patch using a 3D bioprinter. The implanted AI-customized regeneration patch regenerates into identical skin tissue regardless of the patient's age, ethnicity, or skin tone, achieving complete restoration without side effects.
The platform has completed commercialization validation in the South American market. Sales have already been generated in Paraguay. In Chile and Argentina, the technology is being trialed in actual medical settings for patient regenerative treatment. Building on the success proven in these three South American countries, Rokit Healthcare plans to use this year's PSTM 2025 in the United States as a critical milestone for global market expansion.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
